Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0658 EUR
−3.67 M EUR
0.00 EUR
55.03 M
About Oryzon Genomics SA
Sector
Industry
CEO
Carlos Manuel Buesa Arjol
Website
Headquarters
Barcelona
Founded
2000
ISIN
ES0167733015
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of A2ACV2 is 2.7300 EUR — it has increased by 1.49% in the past 24 hours. Watch Oryzon Genomics SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Oryzon Genomics SA stocks are traded under the ticker A2ACV2.
A2ACV2 stock has risen by 3.02% compared to the previous week, the month change is a 3.80% rise, over the last year Oryzon Genomics SA has showed a 49.02% increase.
We've gathered analysts' opinions on Oryzon Genomics SA future price: according to them, A2ACV2 price has a max estimate of 12.00 EUR and a min estimate of 4.35 EUR. Watch A2ACV2 chart and read a more detailed Oryzon Genomics SA stock forecast: see what analysts think of Oryzon Genomics SA and suggest that you do with its stocks.
A2ACV2 reached its all-time high on Feb 25, 2025 with the price of 3.9050 EUR, and its all-time low was 1.3700 EUR and was reached on Feb 3, 2025. View more price dynamics on A2ACV2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
A2ACV2 stock is 2.59% volatile and has beta coefficient of 0.44. Track Oryzon Genomics SA stock price on the chart and check out the list of the most volatile stocks — is Oryzon Genomics SA there?
Today Oryzon Genomics SA has the market capitalization of 208.90 M, it has decreased by −3.78% over the last week.
Yes, you can track Oryzon Genomics SA financials in yearly and quarterly reports right on TradingView.
Oryzon Genomics SA is going to release the next earnings report on Oct 23, 2025. Keep track of upcoming events with our Earnings Calendar.
Oryzon Genomics SA revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
A2ACV2 net income for the last quarter is 103.34 K EUR, while the quarter before that showed −1.70 M EUR of net income which accounts for 106.09% change. Track more Oryzon Genomics SA financial stats to get the full picture.
No, A2ACV2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 8, 2025, the company has 46 employees. See our rating of the largest employees — is Oryzon Genomics SA on this list?
Like other stocks, A2ACV2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oryzon Genomics SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oryzon Genomics SA technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oryzon Genomics SA stock shows the strong buy signal. See more of Oryzon Genomics SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.